MapLight Therapeutics, Inc.
MPLTHealthcareNASDAQBiotechnology · Last scanned Sep 8, 2026
Scan Results
Daily timeframeMapLight Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company for patients suffering from debilitating central nervous system disorders. The $638.6M market capitalization puts MPLT squarely in small-cap range for its industry. The company's products include ML-007C-MA, a fixed-dose combination of an M 1 /M 4 muscarinic agonist for the treatment of schizophrenia and Alzheimer's disease psychosis; ML-004 for the treatment of social communication deficit and/or irritability in autism spectrum disorder; ML-021 for the treatment of motor deficits in Parkinson's disease; ML-055 for the treatment of neuropsychiatric conditions; and ML-009, a G-protein-coupled receptor 52 positive allosteric modulator for the treatment of hyperactivity, impulsivity and agitation-related disorders.
Market Cap
$638.6M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-4.18
EPS (TTM)
$-19.96
EPS (Fwd)
$-3.30
ROE
-111.5%
ROA
-67.1%
Cash
$304.7M
Total Debt
$2.0M
Free CF
-$95.2M
52W Change
-24.9%
Annual Financials
Cash vs Debt
Where MPLT stands vs its 150-day and 200-day moving averages
As of the August 20, 2026 close, MPLT finished 49.21% below its 150-day moving average ($23.92) and 45.12% below its 200-day moving average ($22.14). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is MPLT overbought or oversold?
At the August 20, 2026 close, MPLT's RSI(14) was 34.2, in neutral territory (between 30 and 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
The balance sheet looks solid with $304.7M in cash comfortably exceeding the $2.0M debt load. A net cash position generally provides financial flexibility during uncertain economic periods. Free cash flow is running at -$95.2M, which bears watching. Negative free cash flow can be acceptable during heavy investment periods but needs to improve over time. Return on equity stands at -111.5%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits.
The strong cash position relative to debt provides a financial cushion that reduces balance sheet risk. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. Understanding these risk dimensions helps frame what to watch going forward as conditions evolve for MapLight Therapeutics, Inc. and its sector.